Coagulation inhibitors.

J J Corrigan

Home/Archive/PubMed

PubMed · 6776839

Coagulation inhibitors.

J J Corrigan

View original source ↗Export metadata ↓

Abstract

A number of types of coagulation inhibitors can be seen in autoimmune states. These inhibitors can produce hypocoagulability by at least three mechanisms: by acting as a circulating anticoagulant; by the production of a functionally abnormal procoagulant; or, by the occurrence of an isolated reduction in the plasma level of a coagulation factor. The most common is the circulating anticoagulant which acts by either neutralizing a specific blood coagulation factor or by interfering in some fashion with coagulation factor interactions. The different types of coagulation inhibitors, their laboratory, and clinical manifestations are discussed.

Explore related subjects

Autoimmune Diseases Blood Coagulation Blood Coagulation Factors Factor IX Factor V Factor VIII Humans Lupus Erythematosus, Systemic Partial Thromboplastin Time Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J J Corrigan. 1980. Coagulation inhibitors.. https://pubmed.ncbi.nlm.nih.gov/6776839/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Current concepts in the treatment of autoimmune pancreatitis.

Autoimmune pancreatitis is a recently described chronic inflammatory disease of the pancreas which appears to be part of a systemic disorder characterized by a lymphoplasmacytic infiltrate in affected organs that is rich in IgG4 positive cells. The inflammatory component of the disease appears to resolve with steroid treatment, though relapses do occur. Here we briefly discuss the role of steroid therapy in the management of autoimmune pancreatitis.

Autoimmune Diseases↗

PubMed2007

A syndrome of immunodeficiency, autoimmunity, and spondylometaphyseal dysplasia.

We treated a 5-year-old boy, in our hospital in south India, who had a history of recurrent respiratory infections, tuberculosis, and severe varicella infection. He was short in build and a radiological examination revealed evidence of spondylometaphyseal dysplasia. Investigation of the immune system was suggestive of compromised cellular immunity. Immunofluorescence and immunoblot assay for antibodies detected underlying multiple disorders such as systemic lupus erythematosus (SLE), autoimmune thrombocytopenia, and juvenile rheumatoid arthritis (JRA). Roifman et al. described a similar syndrome in 2000 and 2003, which was characterized by spondylometaphyseal dyplasia, combined immunodeficiency, and autoimmunity and called it Roifman-Costa syndrome (OMIM 607944). Hence a diagnosis of Roifman-Costa syndrome was made. Ours shall be the first report of such a condition from the Indian subcontinent and hence the communication.

Autoimmune Diseases↗

PubMed2007

B cell depletion therapy in autoimmune diseases.

Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. A critical part of this expanding knowledge is the realization that B-cells can be responsible, at least in part, for diseases in which they had not been previously suspected and that their pathogenic influence can be mediated by multiple mechanisms. In turn, the availability of effective agents capable of inducing profound and long-lasting B-cell depletion and the safety and efficacy of Rituximab in non-Hodgkin lymphoma has prompted investigators to use this therapeutic approach in a large number of autoimmune diseases. Thus far, the results have been very promising, and in some cases nothing short of spectacular. In this review, we shall discuss the roles of B-cells in health and disease and the available evidence regarding the efficacy of B-cell depletion in human autoimmunity. Finally, we will discuss some of the many challenges and opportunities that the medical and scientific community should address in the foreseeable future.

Autoimmune Diseases↗